Inhibikase Therapeutics (IKT) Equity Ratio (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Equity Ratio data on file, last reported at 0.97 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.97, up 6.35% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.97 (up 6.35% YoY), and the FY2025 annual result was 0.95, down 0.83% from the prior year.
• Equity Ratio climbed to 0.97 in Q1 2026 per IKT's latest filing, from 0.95 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.97 in Q1 2026 and troughed at 0.12 in Q3 2024.
• A 5-year average of 0.8 and a median of 0.88 in 2022 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio tumbled 114.43% in 2024, then jumped 855.51% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.84 in 2022, then dropped by 10.29% to 0.76 in 2023, then climbed by 27.14% to 0.96 in 2024, then declined by 0.83% to 0.95 in 2025, then climbed by 1.35% to 0.97 in 2026.
• Business Quant data shows IKT's Equity Ratio at 0.97 in Q1 2026, 0.95 in Q4 2025, and 0.92 in Q3 2025.